AR068338A1 - Metodos y sistemas para tratar trastornos de proliferacion celular utilizando absorcion simultanea de dos fotones - Google Patents
Metodos y sistemas para tratar trastornos de proliferacion celular utilizando absorcion simultanea de dos fotonesInfo
- Publication number
- AR068338A1 AR068338A1 ARP080103433A ARP080103433A AR068338A1 AR 068338 A1 AR068338 A1 AR 068338A1 AR P080103433 A ARP080103433 A AR P080103433A AR P080103433 A ARP080103433 A AR P080103433A AR 068338 A1 AR068338 A1 AR 068338A1
- Authority
- AR
- Argentina
- Prior art keywords
- energy
- pharmaceutical composition
- pharmaceutical agent
- subject
- activatable
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1085—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient
- A61N2005/1089—Electrons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1085—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient
- A61N2005/1091—Kilovoltage or orthovoltage range photons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Radiology & Medical Imaging (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Un método para tratar un trastorno de proliferacion celular en un sujeto, que comprende: (1) administrar al sujeto al menos un agente farmacéutico activable que es capaz de activacion por un evento de absorcion simultánea de dos fotones y de efectuar un cambio celular predeterminado cuando se activa; y (2) aplicar al sujeto una energía de iniciacion desde una fuente de energía de iniciacion, donde la energía de iniciacion es capaz de penetrar completamente a través del sujeto, y donde la energía de iniciacion aplicada activa el agente activable por el evento de absorcion simultánea de dos fotones in situ, permitiendo de este modo que se produzca el cambio celular predeterminado, donde el cambio celular predeterminado trata el trastorno relacionado proliferacion celular, y un kit para llevar a cabo el método, un sistema implementado por computadora para realizar el método, una composicion farmacéutica para ser utilizada en el método y un método para originar un efecto de autovacuna un sujeto que utiliza el método. Reivindicacion 33:El método de la reivindicacion 28, donde el al menos un agente de modulacion de energía es uno o más seleccionado de una nanopartícula metálica de fluorescencia biocompatible, molécula colorante de fluorescencia, nanopartícula dorada, un punto cuántico hidrosoluble encapsulado por dendrímeros de poliamidoamina, una luciferasa, una molécula fosforescente biocompatible, una molécula cosechadora de energía electromagnética combinada, y un quelato lantánido capaz de luminiscencia intensa. Reivindicacion 121: Un sistema para producir una autovacuna en un sujeto, que comprende: al menos un agente farmacéutico activable que es capaz de activacion por un evento de absorcion simultánea de dos fotones y de inducir un cambio celular predeterminado en una célula blanco en dicho sujeto; medios para colocar dicho al menos un agente farmacéutico activable en dicho sujeto; y una fuente de energía de iniciacion para proveer energía de iniciacion capaz de activar el al menos un agente farmacéutico activable en dicha célula blanco por el evento de absorcion simultánea de dos fotones, donde la activacion es directa o indirecta. Reivindicacion 149: Un sistema implementado por computadora, que comprende: una unidad de procesamiento central (CPU) que tiene un medio de almacenamiento sobre el cual se provee: una base de datos de compuestos excitables; un primer modulo de computacion para identificar y disenar un compuesto excitable que es capaz de activacion por un evento de absorcion simultánea de dos fotones y de unirse con una estructura o componente celular blanco; y un segundo modulo de computacion que predice la energía de absorcion por resonancia del compuesto excitable, donde el sistema, al cabo de la seleccion de una estructura o componente celular blanco, computa un compuesto excitable que es capaz de activacion por el evento de absorcion simultánea de dos fotones y de unirse con la estructura blanco seguido de una computacion para predecir la energía de absorcion por resonancia del compuesto excitable. Reivindicacion 169: Una composicion farmacéutica para tratar un trastorno de proliferacion celular, que comprende: al menos un agente farmacéutico activable capaz de activacion por un evento de absorcion simultánea de dos fotones y de originar un cambio celular predeterminado; al menos un aditivo que tiene un efecto diagnostico o terapéutico complementario, donde dicho aditivo es al menos un componente seleccionado del grupo integrado por antioxidantes, adyuvantes, fuentes de energía química, y combinaciones de los mismos; y un vehículo aceptable para uso farmacéutico. Reivindicacion 171: La composicion farmacéutica de la reivindicacion 169, donde el al menos un agente farmacéutico activable se selecciona de psoralens, pireno colesteriloleato, acridina, porfirina, fluoresceina, rodamina, 16-diazorcortisona, etidio, complejos metálicos de transicion de bleomicina, complejos metálicos de transicion de deglicobleomicina complejos de organoplatino, aloxazinas, vitamina Ks, vitamina L, metabolitos vitamínicos, precursores vitamínicos, naftoquinonas, naftalenos, naftoles y derivados de los mismos que tienen conformaciones moleculares planas, porforinporfirinas, colorantes y derivados de fenotiazina, cumarinas, quinolonas, quinonas, y antroquinonas. Reivindicacion 172: La composicion farmacéutica de la reivindicacion 171, donde el al menos un agente farmacéutico activable es un psoralen, una cumarina, una porfirina, o un derivado de los mismos. Reivindicacion 173: La composicion farmacéutica de la reivindicacion 171, donde el al menos un agente farmacéutico activable es 8-MOP o AMT. Reivindicacion 174: La composicion farmacéutica de la reivindicacion 169, donde el al menos un agente farmacéutico activable es uno seleccionado de 7,8-dimetil-10-ribitil, isoaloxazina, 7,8,10-trimetilisoaloxazina, 7,8-dimetilaloxazina, dinucleotido isoaloxazina-adenina, mononucleotido de aloxazina, tetrasulfonato de aluminio (III) tfalocianina, hematoporfirina, y ftadocianina. Reivindicacion 175: La composicion farmacéutica de la reivindicacion 169, donde el al menos un agente farmacéutico activable se acopla a un vehiculo que es capaz de unirse a un sitio receptor. Reivindicacion 176: La composicion farmacéutica de la reivindicacion 175, donde el vehículo es uno seleccionado de insulina, interleuquina, timopoyetina o transferrina. Reivindicacion 177: La composicion farmacéutica de la reivindicacion 175, donde el al menos un agente farmacéutico activable se acopla al vehículo mediante un enlace covalente. Reivindicacion 182: La composicion farmacéutica de la reivindicacion 169, donde el al menos un agente farmacéutico activado origina un efecto de autovacuna en el sujeto que reacciona con una célula blanco. Reivindicacion 183: La composicion farmacéutica de la reivindicacion 169, donde el al menos un agente farmacéutico activable es un intercalador de ADN o un derivado halogenado del mismo. Reivindicacion 187: La composicion farmacéutica de la reivindicacion 185, que comprende una pluralidad de agentes de modulacion de energía capaz de convertir la energía de iniciacion, a través de una transferencia de energía de cascada entre la pluralidad de agentes de modulacion de energía, en una energía que activa el al menos un agente farmacéutico activable.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95426307P | 2007-08-06 | 2007-08-06 | |
US12/059,484 US20090104212A1 (en) | 2007-08-06 | 2008-03-31 | Methods and systems for treating cell proliferation disorders using two-photon simultaneous absorption |
Publications (1)
Publication Number | Publication Date |
---|---|
AR068338A1 true AR068338A1 (es) | 2009-11-11 |
Family
ID=40341661
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080103433A AR068338A1 (es) | 2007-08-06 | 2008-08-06 | Metodos y sistemas para tratar trastornos de proliferacion celular utilizando absorcion simultanea de dos fotones |
Country Status (5)
Country | Link |
---|---|
US (1) | US20090104212A1 (es) |
AR (1) | AR068338A1 (es) |
CL (1) | CL2008002307A1 (es) |
TW (1) | TW200914054A (es) |
WO (1) | WO2009020855A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017070197A1 (en) | 2015-10-19 | 2017-04-27 | Immunolight, Llc | X-ray psoralen activated cancer therapy (x-pact) |
US10596387B2 (en) | 2007-04-08 | 2020-03-24 | Immunolight, Llc. | Tumor imaging with X-rays and other high energy sources using as contrast agents photon-emitting phosphors having therapeutic properties |
US8951561B2 (en) | 2007-08-06 | 2015-02-10 | Duke University | Methods and systems for treating cell proliferation disorders using plasmonics enhanced photospectral therapy (PEPST) and exciton-plasmon enhanced phototherapy (EPEP) |
US9358292B2 (en) | 2007-04-08 | 2016-06-07 | Immunolight, Llc | Methods and systems for treating cell proliferation disorders |
US10441810B2 (en) | 2007-04-08 | 2019-10-15 | Immunolight, Llc | X-ray psoralen activated cancer therapy (X-PACT) |
US8376013B2 (en) | 2008-03-11 | 2013-02-19 | Duke University | Plasmonic assisted systems and methods for interior energy-activation from an exterior source |
WO2013009688A1 (en) | 2011-07-08 | 2013-01-17 | Bourke Frederic A | Phosphors and scintillators for light stimulation within a medium |
JP5967935B2 (ja) * | 2008-04-04 | 2016-08-10 | イミュノライト・エルエルシー | insituでのフォトバイオモデュレーションのための非侵襲性システムおよび方法 |
WO2010009106A1 (en) | 2008-07-14 | 2010-01-21 | Bourke Frederic A Jr | Advanced methods and systems for treating cell proliferation disorders |
EP2421376A4 (en) | 2009-04-21 | 2016-04-27 | Immunolight Llc | NON-INVASIVE ENERGY UPGRADING METHODS AND SYSTEMS FOR IN-SITU PHOTO BODY MODULATION |
US10286088B2 (en) | 2011-05-05 | 2019-05-14 | Rutgers, The State University Of New Jersey | Multifunctional infrared-emitting composites |
US20120330291A1 (en) * | 2011-06-24 | 2012-12-27 | The Regents Of The University Of California | Nonlinear optical photodynamic therapy (nlo-pdt) of the cornea |
GB201113815D0 (en) * | 2011-08-10 | 2011-09-28 | Univ Salford The | Multi-photon isomerisation of transcombretastatins |
CA2946386C (en) | 2014-04-22 | 2024-01-02 | Immunolight, Llc | Tumor imaging using photon-emitting phosphors having therapeutic properties |
US11534622B2 (en) * | 2014-08-18 | 2022-12-27 | Immunolight, Llc | Non-invasive systems and methods for selective activation of photoreactive responses |
WO2016115225A1 (en) * | 2015-01-14 | 2016-07-21 | Immunolight, Llc. | Non-invasive systems and methods for treatment of a host carrying a virus with photoactivatable drugs |
JP2017080161A (ja) * | 2015-10-29 | 2017-05-18 | 住友重機械工業株式会社 | 中性子捕捉療法システム |
CN114812808A (zh) * | 2016-11-29 | 2022-07-29 | 光热光谱股份有限公司 | 用于增强光热成像和光谱的方法和设备 |
CN110735333B (zh) * | 2019-11-13 | 2021-11-23 | 常州大学 | 小分子天然染料的新型染-固色方法 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4838852A (en) * | 1987-03-27 | 1989-06-13 | Therakos, Inc. | Active specific immune suppression |
US4979935A (en) * | 1989-02-21 | 1990-12-25 | Quantex Corporation | Method of photodynamic therapy employing electron trapping material |
US5120649A (en) * | 1990-05-15 | 1992-06-09 | New York Blood Center, Inc. | Photodynamic inactivation of viruses in blood cell-containing compositions |
US5980954A (en) * | 1992-02-07 | 1999-11-09 | Vasogen Ireland Limited | Treatment of autoimmune diseases |
US6204058B1 (en) * | 1992-02-07 | 2001-03-20 | Vasogen Ireland Limited | Treatment of autoimmune diseases |
US6669965B2 (en) * | 1992-02-07 | 2003-12-30 | Vasogen Ireland Limited | Method of treating atherosclerosis |
US5807881A (en) * | 1992-05-27 | 1998-09-15 | Quadra Logic Technologies, Inc. | Method for selectively reducing activated leukocyte cell population |
US6235508B1 (en) * | 1995-06-07 | 2001-05-22 | Baxter International Inc. | Method of inactivation of viral and bacterial blood contaminants |
IT1275571B (it) * | 1995-07-19 | 1997-08-07 | Consiglio Nazionale Ricerche | Substrati fluorogenici suscettibili di fotoattivazione previa trasformazione per via enzimatica atti alla diagnosi ed alla terapia fotodinamica dei tumori |
US5829448A (en) * | 1996-10-30 | 1998-11-03 | Photogen, Inc. | Method for improved selectivity in photo-activation of molecular agents |
US6331286B1 (en) * | 1998-12-21 | 2001-12-18 | Photogen, Inc. | Methods for high energy phototherapeutics |
US5957960A (en) * | 1997-05-05 | 1999-09-28 | Light Sciences Limited Partnership | Internal two photon excitation device for delivery of PDT to diffuse abnormal cells |
US6071944A (en) * | 1997-11-12 | 2000-06-06 | Bowling Green State University | Method of treatment of pigmented cancer cells utilizing photodynamic therapy |
US7045124B1 (en) * | 1999-01-12 | 2006-05-16 | Vasogen Irelend Limited | Pre-conditioning against cell death |
US6602274B1 (en) * | 1999-01-15 | 2003-08-05 | Light Sciences Corporation | Targeted transcutaneous cancer therapy |
US6719778B1 (en) * | 2000-03-24 | 2004-04-13 | Endovascular Technologies, Inc. | Methods for treatment of aneurysms |
US20020127224A1 (en) * | 2001-03-02 | 2002-09-12 | James Chen | Use of photoluminescent nanoparticles for photodynamic therapy |
US8618595B2 (en) * | 2001-07-02 | 2013-12-31 | Merck Patent Gmbh | Applications of light-emitting nanoparticles |
US20030108543A1 (en) * | 2001-12-12 | 2003-06-12 | Lewandowski Leon J. | Photophoretic auto immune stimulation |
DE10163719C2 (de) * | 2001-12-21 | 2003-12-18 | Sarstedt Ag & Co | Blutentnahmevorrichtung |
GB0215534D0 (en) * | 2002-07-04 | 2002-08-14 | Ecole Polytech | Selective photochemotherapy using oligonucleotide targeting agents |
US20050085455A1 (en) * | 2003-10-16 | 2005-04-21 | Light Sciences Corporation | Photodynamic therapy for local adipocyte reduction |
US9358292B2 (en) * | 2007-04-08 | 2016-06-07 | Immunolight, Llc | Methods and systems for treating cell proliferation disorders |
-
2008
- 2008-03-31 US US12/059,484 patent/US20090104212A1/en not_active Abandoned
- 2008-08-01 WO PCT/US2008/071920 patent/WO2009020855A1/en active Application Filing
- 2008-08-05 CL CL2008002307A patent/CL2008002307A1/es unknown
- 2008-08-06 TW TW097129966A patent/TW200914054A/zh unknown
- 2008-08-06 AR ARP080103433A patent/AR068338A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20090104212A1 (en) | 2009-04-23 |
WO2009020855A1 (en) | 2009-02-12 |
CL2008002307A1 (es) | 2009-03-06 |
TW200914054A (en) | 2009-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR068338A1 (es) | Metodos y sistemas para tratar trastornos de proliferacion celular utilizando absorcion simultanea de dos fotones | |
AR066899A1 (es) | Metodos y disposiciones para el tratamiento de trastornos de proliferacion celular | |
Zhu et al. | Zwitterionic AIEgens: Rational Molecular Design for NIR‐II Fluorescence Imaging‐Guided Synergistic Phototherapy | |
Huang et al. | Expanding anti‐Stokes shifting in triplet–triplet annihilation upconversion for in vivo anticancer prodrug activation | |
Liu et al. | Hypoxia induced by upconversion‐based photodynamic therapy: towards highly effective synergistic bioreductive therapy in tumors | |
Zhu et al. | Anti-Stokes shift luminescent materials for bio-applications | |
Dai et al. | In vivo multimodality imaging and cancer therapy by near-infrared light-triggered trans-platinum pro-drug-conjugated upconverison nanoparticles | |
Starkewolf et al. | X-ray triggered release of doxorubicin from nanoparticle drug carriers for cancer therapy | |
Hirschberg et al. | Disruption of the blood–brain barrier following ALA‐mediated photodynamic therapy | |
AR076361A1 (es) | Composicion farmaceutica. kit. metodos y sistemas de conversion ascendente de energia no invasivos para la fotobiomodulacion in-situ | |
AR070461A1 (es) | Metodos y sistemas para tratar trastornos de proliferacion celular usando terapia fotoespectral mejorada con plasmonicos (pepst) y fototerapia mejorada con excitones plasmones (epep). composiciones. | |
JP2002534218A5 (es) | ||
ATE535219T1 (de) | Kombinierte photokoagulations- und photodynamische therapie | |
ES2249888T3 (es) | Conjugados de paclitaxel solubles en agua, combinados con irradiacion para el tratamiento del cancer. | |
ATE290882T1 (de) | Pharmazeutische mischung gegen krebs, die ein 4- chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthält | |
Jiang et al. | Diketopyrrolopyrrole: An emerging phototherapy agent in fighting cancer | |
Zavadskaya | Photodynamic therapy in the treatment of glioma | |
Hou et al. | Long wavelength light activated prodrug conjugates for biomedical applications | |
Cao et al. | Multifunctional hybrid hydrogel system enhanced the therapeutic efficacy of treatments for postoperative glioma | |
Li et al. | Near-infrared boron–dipyrrin (BODIPY) nanomaterials: Molecular design and anti-tumor therapeutics | |
Singh et al. | Photoresponsive polymeric microneedles: An innovative way to monitor and treat diseases | |
AR049135A1 (es) | Composicion,metodo, kit y tratamiento con oxaliplatino y un inhibidor del egfr,como erlotinib | |
Ebert et al. | Intravital microscopic research of microembolization with degradable starch microspheres | |
Kim et al. | A Light‐Driven Anti‐Cancer Dual‐Therapeutic Cassette Enhances Solid Tumour Regression | |
He et al. | Intravital microscopic analysis of vascular perfusion and macromolecule extravasation after photodynamic vascular targeting therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |